Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...
Strong Buy Rating for Travere Therapeutics Backed by Filspari’s Market Potential and Full FDA Approval
Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...
FiercePharma7d
Travere pumps brakes on late-stage enzyme replacement therapy study, citing production scale-up problems
Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...
GlobalData on MSN28d
After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari ...
FiercePharma29d
Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with Novartis
The FDA has converted Filspari’s conditional nod in the kidney disease IgA nephropathy (IgAN) into a full approval. As part of the conversion Thursday, the FDA has removed a specific urine ...
Business Wire28d
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function ...
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...
Monthly Prescribing Reference29d
Filspari Approved to Slow Kidney Function Decline in IgA Nephropathy
The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ...
pharmaphorum1mon
Travere weaker after Filspari fails confirmatory trial
Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...
PMLiVE26d
FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy
The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...